Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

SciFluor Life Sciences presents new integrin receptor antagonists

Sep. 19, 2019

Claudin-5 is a key mediator of retinal pigment epithelium pathology regulated by the circadian clock

Sep. 18, 2019

Adverum reports 24-week cohort 1 data from phase I study of ADVM-022 in wet AMD

Sep. 12, 2019

Phase II results support further study of AAV2-REP1 gene therapy in patients with choroideremia

Sep. 9, 2019

A reverse engineering approach for in vitro modeling of the human eye

Sep. 2, 2019

Novel Chemerin GPCR agonist OK-113 exhibits anti-inflammatory activity in DED mouse model

Aug. 30, 2019

Novel mouse model of human optic atrophy syndrome

Aug. 23, 2019

Aerie initiates first-in-human study of AR-13503 sustained-release intravitreal Implant

Aug. 21, 2019

Oxurion reports topline results from phase IIa study of THR-317 plus ranibizumab in DME

Aug. 20, 2019

Redx Pharma presents Rho-associated protein kinase inhibitors

Aug. 19, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for March 4, 2025
NIH changes set industry up for workforce, ideas drought
BioWorld
On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...
Roche looks to grow with sequencing by expansion tech
BioWorld MedTech
Roche Holding AG revealed plans to launch its sequencing by expansion technology next year, raising the possibility that rival Illumina Inc. could face a real run...
Magnet, Eli Lilly sign $1.25B molecular glue deal for oncology
BioWorld
About 17 months after emerging from stealth with its Trueglue discovery platform, Magnet Biomedicine Inc. has joined with Eli Lilly and Co. to discover, develop...